Abstract
The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Current Pharmaceutical Design
Title: Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors
Volume: 18 Issue: 7
Author(s): Bernhard Wunsch
Affiliation:
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Abstract: The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Export Options
About this article
Cite this article as:
Wunsch Bernhard, Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436548
DOI https://dx.doi.org/10.2174/138161212799436548 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
OA-4 Inhibits Osteoclast Formation and Bone Resorption via Suppressing RANKL Induced P38 Signaling Pathway
Current Medicinal Chemistry Therapeutic Potential of Carbon Monoxide (CO) for Intestinal Inflammation
Current Medicinal Chemistry Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) An Update on JAK Inhibitors
Current Medicinal Chemistry Mammographic and Sonographic Features of Breast Cancer in Women Before 30 Years of Age
Current Medical Imaging LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Design, Synthesis, Anti-Proliferative Evaluation and Cell Cycle Analysis of Hybrid 2-Quinolones
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy Design, Synthesis and Antitumor Activity of Dimeric Bile Acid-Amino Acid Conjugates
Letters in Organic Chemistry PPARγ-targeting Potential for Radioprotection
Current Drug Targets Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine